
News|Articles|January 1, 2008
Sapropterin (Kuvan): Synthetic form of tetrahydrobiopterin approved for the treatment of PKU
FDA approved sapropterin on December 13, 2007, to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due ro BH4-responsive phenylketonuria (PKU).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transparency paves the way for lower costs and equitable access
2
New self-injectable biologics promise cost savings and patient convenience
3
World AIDS Day: 10 things to know about AIDS in 2025
4
Evaluating Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease: Written Recap
5






















































